Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)41.32
  • Today's Change3.07 / 8.03%
  • Shares traded8.94m
  • 1 Year change-47.14%
  • Beta1.5959
Data delayed at least 15 minutes, as of Nov 22 2024 17:50 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform9
Hold15
Sell2
Strong Sell1

Share price forecast in USD

The 22 analysts offering 12 month price targets for Moderna Inc have a median target of 62.00, with a high estimate of 212.00 and a low estimate of 31.00. The median estimate represents a 62.09% increase from the last price of 38.25.
High454.2%212.00
Med62.1%62.00
Low-19.0%31.00

Earnings history & estimates in USD

On Nov 07, 2024, Moderna Inc reported 3rd quarter 2024 earnings of 0.03 per share. This result exceeded the -1.91 consensus loss of the 17 analysts covering the company and outperformed last year's 3rd quarter results by 9.56.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate-8.47%
Moderna Inc reported annual 2023 losses of -12.33 per share on Feb 22, 2024.
Average growth rate-27.67%
More ▼

Revenue history & estimates in USD

Moderna, Inc. had 3rd quarter 2024 revenues of 1.86bn. This bettered the 1.25bn consensus of the 15 analysts covering the company. This was the same as the prior year's 3rd quarter results.
Average growth rate+169.10%
Moderna, Inc. had revenues for the full year 2023 of 6.85bn. This was 64.45% below the prior year's results.
Average growth rate+843.32%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.